Figure 3. Estimated Breast Cancer–Specific Survival After Metastatic Recurrence and 5-Year Distant Recurrence-Free Survival by ER/ERBB2 Status.

A, Model-estimated median breast cancer–specific survival after metastatic recurrence. Pertuzumab and trastuzumab emtansine were introduced for ERBB2+ subtypes in 2012. Model means are computed across all 4 models, equally weighted; individual model results are shown in eTable 6 in Supplement 1. B, Model-estimated mean 5-year distant recurrence-free survival. Trastuzumab was introduced for ERBB2+ subtypes in 2005. Model means are computed across all 4 models, equally weighted; individual model results are shown in eTable 7 in Supplement 1.